Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL A Randomized, Open Phase II Trial
Status:
RECRUITING
Trial end date:
2027-12-04
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL